In the post-marketing experience, some cases of overdose were reported (from 40-800 mg of lercanidipine, including reports of suicide attempt).
As with other dihydropyridines, overdosage might be expected to cause excessive peripheral vasodilatation.
Symptoms associated to overdose include marked hypotension, dizziness, fatigue and reflex tachycardia.
Cardiac failure, myocardial ischemia and acute renal failure might occur. In case of severe hypotension, cardiovascular support could be helpful.
In view of the prolonged pharmacological effect of lercanidipine, it is essential that the cardiovascular status of patients who take an overdose is monitored for 24 hrs at least. There is no information on the value of dialysis. Since the drug is highly lipophilic, it is most probable that plasma levels are no guide to the duration of the period of risk and dialysis may not be effective.